Patents by Inventor Noura Abul-Husn

Noura Abul-Husn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M Variation
    Publication number: 20230383353
    Abstract: The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.
    Type: Application
    Filed: May 30, 2023
    Publication date: November 30, 2023
    Inventors: Yurong Xin, Jesper Gromada, Xiping Cheng, Frederick Dewey, Tanya Teslovich Dostal, Claudia Schurmann, Aris Baras, Noura Abul-Husn
  • Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
    Patent number: 11702700
    Abstract: The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: July 18, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Yurong Xin, Jesper Gromada, Xiping Cheng, Frederick Dewey, Tanya Teslovich Dostal, Claudia Schurmann, Aris Baras, Noura Abul-Husn
  • Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M Variation
    Publication number: 20210246508
    Abstract: The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.
    Type: Application
    Filed: February 18, 2021
    Publication date: August 12, 2021
    Inventors: Yurong Xin, Jesper Gromada, Xiping Cheng, Frederick Dewey, Tanya Teslovich Dostal, Claudia Schurmann, Aris Baras, Noura Abul-Husn
  • Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
    Patent number: 10961583
    Abstract: The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: March 30, 2021
    Assignee: Regeneron Phramaceuticals, Inc.
    Inventors: Yurong Xin, Jesper Gromada, Xiping Cheng, Frederick Dewey, Tanya Teslovich Dostal, Claudia Schurmann, Aris Baras, Noura Abul-Husn